| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Institut für Humangenetik [F. T., B. H., D. R. L., M. Z.], Institut für Medizinische Informatik, Biometrie und Epidemiologie [J. H., T. H., E. K., I. G. D., K-H. J.]; and Zentrum für Augenheilkunde [G. A., H. S., N. B.], Universitätsklinikum Essen, 45122 Essen, Germany
Uveal melanoma is the most common intraocular malignancy. About 50% of patients die of metastases, which almost exclusively originate from primary tumors that have lost one chromosome 3 (monosomy 3). To gain insight into the biological mechanisms that underlie the various metastasizing potential of uveal melanoma, we have determined gene expression levels in 20 primary tumors using oligonucleotide microarrays containing 12500 probe sets. The expression measurements of those 7902 genes that were expressed in more than 10% of tumors were analyzed using two different statistical approaches. We used a modified Wilcoxon rank-sum test to identify genes differentially expressed between tumors with and without monosomy 3. Seven genes showed complete loss of expression in tumors with monosomy 3 but were expressed in tumors with disomy 3. Two of them, CHL1 and fls485, are located within or close to the uveal melanoma susceptibility locus UVM2 at 3p25. However, mutation analysis of both genes in eight tumors with monosomy 3 did not reveal structural or epigenetic alteration. To identify tumor classes, we performed unsupervised hierarchical cluster analysis; this approach separated uveal melanomas into two groups. We found that this classification is strikingly robust because, when tested by "resampling," the same grouping is obtained from 47 of 50 subsamples of genes. In clusterings of the three remaining subsamples, the grouping of only one tumor does not conform with the original classification. Excluding this tumor, cluster analyses of subsamples containing as few as 300 randomly chosen genes consistently result in the same classification, thus indicating that the difference between the two tumor classes is pervasive. Interestingly, all of the tumors in one of the groups have disomy 3, whereas all of the others have monosomy 3. Our findings suggest that there are two distinct entities of uveal melanoma that were previously unrecognized because they are not obviously distinguishable by clinicopathological features.
This article has been cited by other articles:
![]() |
J. Trolet, P. Hupe, I. Huon, I. Lebigot, C. Decraene, O. Delattre, X. Sastre-Garau, S. Saule, J.-P. Thiery, C. Plancher, et al. Genomic Profiling and Identification of High-Risk Uveal Melanoma by Array CGH Analysis of Primary Tumors and Liver Metastases Invest. Ophthalmol. Vis. Sci., June 1, 2009; 50(6): 2572 - 2580. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W. Mensink, J. Vaarwater, E. Kilic, N. C. Naus, N. Mooy, G. Luyten, H. T. Bruggenwirth, D. Paridaens, and A. de Klein Chromosome 3 Intratumor Heterogeneity in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., February 1, 2009; 50(2): 500 - 504. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Onken, L. A. Worley, M. D. Long, S. Duan, M. L. Council, A. M. Bowcock, and J. W. Harbour Oncogenic Mutations in GNAQ Occur Early in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5230 - 5234. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. van Gils, E. M. Lodder, H. W. Mensink, E. Kilic, N. C. Naus, H. T. Bruggenwirth, W. van IJcken, D. Paridaens, G. P. Luyten, and A. de Klein Gene Expression Profiling in Uveal Melanoma: Two Regions on 3p Related to Prognosis Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4254 - 4262. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ulmer, J. Beutel, D. Susskind, R.-D. Hilgers, F. Ziemssen, M. Luke, M. Rocken, M. Rohrbach, G. Fierlbeck, K.-U. Bartz-Schmidt, et al. Visualization of Circulating Melanoma Cells in Peripheral Blood of Patients with Primary Uveal Melanoma Clin. Cancer Res., July 15, 2008; 14(14): 4469 - 4474. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sekulic, P. Haluska Jr, A. J. Miller, J. G. De Lamo, S. Ejadi, J. S. Pulido, D. R. Salomao, E. C. Thorland, R. G. Vile, D. L. Swanson, et al. Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape Mayo Clin. Proc., July 1, 2008; 83(7): 825 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Maat, L. V. Ly, E. S. Jordanova, D. de Wolff-Rouendaal, N. E. Schalij-Delfos, and M. J. Jager Monosomy of Chromosome 3 and an Inflammatory Phenotype Occur Together in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 505 - 510. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. V. Sharma, J. E. Gould, J. W. Harbour, G. P. Linette, T. K. Pilgram, P. N. Dayani, and D. B. Brown Hepatic Arterial Chemoembolization for Management of Metastatic Melanoma Am. J. Roentgenol., January 1, 2008; 190(1): 99 - 104. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Meir, R. Dror, X. Yu, J. Qian, I. Simon, J. Pe'er, and I. Chowers Molecular Characteristics of Liver Metastases from Uveal Melanoma Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 4890 - 4896. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D Singh, K. Sisley, Y. Xu, J. Li, P. Faber, S. J Plummer, H. S Mudhar, I. G Rennie, P. M Kessler, G. Casey, et al. Reduced expression of autotaxin predicts survival in uveal melanoma Br J Ophthalmol, October 1, 2007; 91(10): 1385 - 1392. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Onken, L. A. Worley, E. Person, D. H. Char, A. M. Bowcock, and J. W. Harbour Loss of Heterozygosity of Chromosome 3 Detected with Single Nucleotide Polymorphisms Is Superior to Monosomy 3 for Predicting Metastasis in Uveal Melanoma Clin. Cancer Res., May 15, 2007; 13(10): 2923 - 2927. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Meir, M. Zeschnigk, L. Masshofer, J. Pe'er, and I. Chowers The Spatial Distribution of Monosomy 3 and Network Vasculogenic Mimicry Patterns in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 1918 - 1922. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Bosch, J. A. Thompson, M. K. Srivastava, U. K. Iheagwara, T. G. Murray, M. Lotem, B. R. Ksander, and S. Ostrand-Rosenberg MHC Class II-Transduced Tumor Cells Originating in the Immune-Privileged Eye Prime and Boost CD4+ T Lymphocytes that Cross-react with Primary and Metastatic Uveal Melanoma Cells Cancer Res., May 1, 2007; 67(9): 4499 - 4506. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Worley, M. D. Onken, E. Person, D. Robirds, J. Branson, D. H. Char, A. Perry, and J. W. Harbour Transcriptomic versus Chromosomal Prognostic Markers and Clinical Outcome in Uveal Melanoma Clin. Cancer Res., March 1, 2007; 13(5): 1466 - 1471. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Onken, L. A. Worley, R. M. Davila, D. H. Char, and J. W. Harbour Prognostic Testing in Uveal Melanoma by Transcriptomic Profiling of Fine Needle Biopsy Specimens J. Mol. Diagn., November 1, 2006; 8(5): 567 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chin, L. A. Garraway, and D. E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era. Genes & Dev., August 15, 2006; 20(16): 2149 - 2182. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Harbour Eye Cancer: Unique Insights into Oncogenesis The Cogan Lecture Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 1737 - 1745. [Full Text] [PDF] |
||||
![]() |
M. D. Onken, J. P. Ehlers, L. A. Worley, J. Makita, Y. Yokota, and J. W. Harbour Functional Gene Expression Analysis Uncovers Phenotypic Switch in Aggressive Uveal Melanomas. Cancer Res., May 1, 2006; 66(9): 4602 - 4609. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Choudhary, M. Brun, J. Hua, J. Lowey, E. Suh, and E. R. Dougherty Genetic test bed for feature selection Bioinformatics, April 1, 2006; 22(7): 837 - 842. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zuidervaart, P. J. Hensbergen, M.-C. Wong, A. M. Deelder, C. P. Tensen, M. J. Jager, and N. A. Gruis Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 786 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Kadkol, A. Y. Lin, V. Barak, I. Kalickman, L. Leach, K. Valyi-Nagy, D. Majumdar, S. Setty, A. J. Maniotis, R. Folberg, et al. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 802 - 806. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Elfilali, S. Lair, C. Verbeke, P. La Rosa, F. Radvanyi, and E. Barillot ITTACA: a new database for integrated tumor transcriptome array and clinical data analysis Nucleic Acids Res., January 1, 2006; 34(suppl_1): D613 - D616. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Ehlers and J. W. Harbour NBS1 Expression as a Prognostic Marker in Uveal Melanoma Clin. Cancer Res., March 1, 2005; 11(5): 1849 - 1853. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nambiar, A. Mirmohammadsadegh, R. Doroudi, A. Gustrau, A. Marini, G. Roeder, T. Ruzicka, and U. R. Hengge Signaling Networks in Cutaneous Melanoma Metastasis Identified by Complementary DNA Microarrays Arch Dermatol, February 1, 2005; 141(2): 165 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Onken, L. A. Worley, J. P. Ehlers, and J. W. Harbour Gene Expression Profiling in Uveal Melanoma Reveals Two Molecular Classes and Predicts Metastatic Death Cancer Res., October 15, 2004; 64(20): 7205 - 7209. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Irwin, G. A. Boorman, M. L. Cunningham, A. N. Heinloth, D. E. Malarkey, and R. S. Paules Application of Toxicogenomics to Toxicology: Basic Concepts in the Analysis of Microarray Data Toxicol Pathol, January 1, 2004; 32(1_suppl): 72 - 83. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |